Focus on Baseline LDL-C and Patient Risk, Not Drug Type: A Perspective on Alirocumab vs Evolocumab.
Saved in:
| Title: | Focus on Baseline LDL-C and Patient Risk, Not Drug Type: A Perspective on Alirocumab vs Evolocumab. |
|---|---|
| Authors: | Sabouret P; Department of Cardiology, Sorbonne University, 75013 Paris, France., Giamundo DM; Department of Systems Medicine, 'Tor Vergata' University, 00133 Rome, Italy., Mamas M; Department of Cardiology, Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust, ST4 6QG Stoke-on-Trent, UK.; Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, ST5 5BG Keele, UK. |
| Source: | Reviews in cardiovascular medicine [Rev Cardiovasc Med] 2026 Apr 21; Vol. 27 (4), pp. 50430. Date of Electronic Publication: 2026 Apr 21 (Print Publication: 2026). |
| Publication Type: | Editorial |
| Journal Info: | Publisher: IMR Press Country of Publication: Singapore NLM ID: 100960007 Publication Model: eCollection Cited Medium: Internet ISSN: 2153-8174 (Electronic) Linking ISSN: 15306550 NLM ISO Abbreviation: Rev Cardiovasc Med Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
